- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02920359
Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control
5. oktober 2017 opdateret af: Rafael de la Torre, Parc de Salut Mar
The study consists of the generation of biological samples (in urine) positive to leuprorelin acetate for doping control by new developed methods, and establish the analytical parameters that reveal the administration of Leuprorelin acetate in healthy volunteers with these methods.
Studieoversigt
Status
Afsluttet
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
5
Fase
- Fase 1
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 45 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Han
Beskrivelse
Inclusion Criteria:
- Healthy male volunteers aged from 18 to 45 years.
- Understanding and accepting the study procedures and signing the informed consent form.
- A health profile devoid of organic or physiological disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- Body mass index (BMI=weigh/height2) will range between 19 and 25 Kg/m2 and weight between 50 and 100 kg. BMI between 25 and 27 kg/m2 can be included by principal investigator criteria.
Exclusion Criteria:
- Non compliance of the inclusion criteria.
- History of allergy, idiosyncrasy, hypersensitivity or adverse reactions to the active substance, similar nonapeptides or any excipients.
- History of allergy or adverse reactions to any medication.
- Subjects for which the drug involved in the study is counter indicated.
- History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- History or clinical evidence of alcoholism, drug abuse, or regular use of psychoactive drugs.
- Have been volunteer in another study with drugs in the last 3 months prior to start this study.
- Have taken part in studies with blood donation in the last 2 months prior to start this study.
- Having suffered any organic disease or major surgery in the six months prior to start this study.
- A prior history of or presence of significant cardiovascular, neurological, haematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease that, in the investigator's opinion, considering the current state of the art, they are clinically significant, are life-threatening for the subjects and could interfere with the product assessment. Especially seizures or a history of epilepsy.
- Regular use of any drug in the month prior to the study sessions, except for vitamins, herbal remedies or dietary supplements if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
- Smokers of more than 20 cigarettes per day in the last 3 months prior to start this study.
- Taking more than 40 g of alcohol per day.
- Drinking more than 5 cups per day of coffee, tea, coke, stimulants or equivalent, or drinks containing xanthines, in the 3 months prior to start this study.
- Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- Subjects with positive serology for hepatitis B, C or HIV.
- Subjects with anormal values of testosterone or prostate-specific antigen according to age normal values.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: LEUPRORELIN ACETATE
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Urine concentrations of leuprorelin acetate
Tidsramme: From the administration to 6 hours post-administration
|
Urine samples will be collected in two intervals after the administration of leuprorelin acetate (0-3h; 3-6h) in all experimental study sessions (3 consecutive days).
|
From the administration to 6 hours post-administration
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
17. november 2016
Primær færdiggørelse (Faktiske)
13. december 2016
Studieafslutning (Faktiske)
30. september 2017
Datoer for studieregistrering
Først indsendt
29. september 2016
Først indsendt, der opfyldte QC-kriterier
29. september 2016
Først opslået (Skøn)
30. september 2016
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
6. oktober 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. oktober 2017
Sidst verificeret
1. oktober 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IMIMFTCL/LEUPRO
- 2016-002719-16 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med LEUPRORELIN ACETATE
-
TakedaRekrutteringCentral tidlig pubertetKina
-
Uppsala UniversityAfsluttetPostoperative komplikationer | Væsketerapi | Væskeoverbelastning | Pancreas sygdom | Postoperativ periodeSverige
-
Daniel VaenaAfsluttetProstatakræft | Kastratresistent prostatakræftForenede Stater
-
Wendell Yap, MDUniversity of Kansas Medical CenterIkke længere tilgængeligProstatakræftForenede Stater
-
Karolinska InstitutetAfsluttet
-
AbbVieAfsluttet
-
University of Alabama at BirminghamIkke rekrutterer endnu
-
University of PennsylvaniaAfsluttetMild kognitiv svækkelseForenede Stater
-
Phoenix Molecular ImagingAfsluttetProstatakræftForenede Stater
-
Children's Hospital of Fudan UniversityAfsluttetIdiopatisk tidlig pubertetKina